Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: SLC6A1-related disorder is a recently identified, rare, genetic neurodevelopmental disorder that is associated with loss-of-function variants in SLC6A1. This gene encodes GABA transporter type I that is responsible for re-uptake of GABA from the synapse into the pre-synaptic terminal or circulating neuroglia. Based upon retrospective review of published cases and available research databases including Epi25 collective and SLC6A1 Connect patient database, the phenotypic spectrum is broad and includes developmental delay, epilepsy, and autism or autistic traits. SLC6A1 is one of the genes included in the Simons Searchlight registry, which includes standardized data collection across genetically identified neurodevelopmental conditions.

Methods: In this study, we compare parent-report measures of phenotypic features in the Simons Searchlight registry to previously published, provider-reported cases to assess if parent-report measures are consistent with what has been reported in the literature.

Results: There were 116 participants in the provider-reported dataset compared to 43 individuals in the caregiver-reported dataset. Carriers in Searchlight had 83 unique pathogenic or likely pathogenic variants in SLC6A1, which were predominantly missense or nonsense variants. There was no significant difference between groups for the prevalence of developmental delay, ASD, or ADHD. Caregivers more often reported hypotonia, while epilepsy was slightly more frequently reported by providers.

Conclusions: We propose that standardized parent-report data collection methods are consistent with provider reports on many core features of SLC6A1-related disorder. The availability of patient registries and standardized natural history studies may fill an important need in clinical trial readiness programs, with larger sample sizes than smaller published case series.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238190PMC
http://dx.doi.org/10.1186/s11689-022-09449-7DOI Listing

Publication Analysis

Top Keywords

simons searchlight
12
slc6a1-related disorder
8
variants slc6a1
8
developmental delay
8
searchlight registry
8
data collection
8
parent-report measures
8
slc6a1
5
consistency parent-report
4
parent-report slc6a1
4

Similar Publications

In conversation with Małgorzata Kosla.

FEBS J

August 2025

The FEBS Journal, Editorial Office, Cambridge, UK.

In this issue of The FEBS Journal, we interviewed Małgorzata 'Gosia' Kosla, who together with her husband Piotr, established the PACS2 Research Foundation when their daughter Lena was diagnosed with the ultrarare PACS2 syndrome as an infant. PACS2 syndrome is a neurodevelopmental disorder caused by de novo pathogenic mutations in the PACS2 gene and is linked to early-onset epilepsy, global developmental delay and cerebellar dysgenesis. According to Simon's Searchlight, as of 2024, around 32 cases have been described in medical research; there are currently no clinically approved therapeutic agents for treating PACS2 syndrome.

View Article and Find Full Text PDF

Introduction: Okur-Chung Neurodevelopmental Syndrome (OCNDS) is an ultra-rare genetic disorder caused by mutations in the gene, which encodes the catalytic subunit of protein kinase CK2α. OCNDS is characterized by global developmental delay, intellectual disability, speech and language deficits, and other multi-system symptoms. Although prior reports have described considerable phenotypic variability, the relationship between specific CK2α variant locations and symptom presentation remains poorly defined.

View Article and Find Full Text PDF

Genetic studies have identified common and rare variants increasing the risk for neurodevelopmental and psychiatric disorders (NPDs). These risk variants have also been shown to influence the structure of the cerebral cortex. However, it is unknown whether cortical differences associated with genetic variants are linked to the risk they confer for NPDs.

View Article and Find Full Text PDF

Background And Objectives: Somatic variants in brain-related genes can cause neurodevelopmental disorders, but detailed characterizations of their clinical phenotypes, neurobehavioral profiles, and comparisons with individuals with germline variants are limited.

Methods: Using data from the Simons Searchlight natural history cohort, which uses standardized parent-report data collection methods, we identified individuals with neurodevelopmental disorders caused by pathogenic somatic variants and examined their phenotypic data. We further used results from standardized measurements of adaptive functioning, social behavior, and emotional and behavioral problems to compare individuals with somatic variants with those with germline variants.

View Article and Find Full Text PDF

The CTNNB1 Connect & Cure and CTNNB1 Foundation, alongside Asociación CTNNB1, CTNNB1 Italia, Association CTNNB1 France, and researchers and clinicians globally are dedicated to finding effective treatments and cures for CTNNB1 syndrome. The syndrome is also characterized by progressive spasticity, which can in some cases cause loss of already achieved motor milestones. Since 2019, they have brought together researchers from different fields and invested in various research efforts to advance the search for treatment solutions for patients with CTNNB1 syndrome.

View Article and Find Full Text PDF